Kailera Therapeutics, Inc.
KLRA$3.07B
Mid CapNASDAQBiotechnology🇺🇸North America145 employees
Drugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
KLRA News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
KAI-9531 | Phase 3 | Obesity With Diabetes | - | - |
Semaglutide | Phase 3 | Obesity | - | - |
KAI-7535 | Phase 2 | Obesity | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply